Our next panel, “Late Stage and Commercial Gene & Cell Therapy Warriors: How They Got to/Crossed the Finish Line” featured Dr. Vishwas Seshadri, CEO of Abeona Therapeutics, Dr. Pad Chivukula, CSO and COO of Arcturus Therapeutics, Andrew Sassine, CFO of Arcturus Therapeutics, Dr. Linda Marban, President & CEO of Capricor Therapeutics, Inc., and Dr. Bobby Gaspar, CEO of Orchard Therapeutics. The panel was moderated by Kristen Kluska and Pete Stavropoulos.

• Dr. Seshadri highlighted the long-term, durable data presented on it’s lead program, EB-101 for recessive dystrophic epidermolysis bullosa, which is currently in a Phase 3 trial.

• Dr. Chivukula and Andrew Sassine discussed Arcturus’ differentiated mRNA and biodegradable lipid nanoparticle platforms, and data supporting the submitted EUA and soon to initiate booster studies for its COVID-19 vaccine ARCT-154.

• Dr. Marbán discussed the lead program, CAP-1002, a cell therapy for late-stage Duchenne Muscular Dystrophy.

• Dr. Gaspar highlighted the power of Orchard’s platform to address neurometabolic diseases, including neurocognitive benefit observed with its approved agent LIBMELDY, which recently launched in the EU.

#Cantor #CantorFitzgerald #CantorHealthcare #CantorConferenceSeries